WuXi PharmaTech, China's largest CRO, is blueprinting forays into two of the hottest locales for U.S. R&D, planning to open offices in Boston and San Francisco.
WuXi PharmaTech is moving toward an IPO for one of its R&D and manufacturing subsidiaries, hoping to take advantage of a new market in its native China.
WuXi PharmaTech has spent the last year and change amping up its genomics expertise, and now China's largest CRO has signed a deal with Cambridge, MA's NextCODE Health to further grow its bioinformatics offerings.
Chinese CRO WuXi PharmaTech is forecasting a better-than-expected 2014 after a strong third quarter and some timely deals, moving into the new year with hopes for continued global growth.
Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.
WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.
Aldea Pharmaceuticals closed a $24 million round of Series B equity financing to support the development of a drug designed to mitigate the severe--and sometimes deadly--effects of alcohol poisoning.
WuXi PharmaTech, China's largest CRO, boosted its revenue by 14.8% in the second quarter, as banner growth in its contract manufacturing business helped the company expand its global reach.
WuXi PharmaTech has increased its manufacturing capabilities in China, bolstering its fastest-growing business as it looks to expand around the globe.